Black Diamond Therapeutics (BDTX) vs Champions Oncology (CSBR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Champions Oncology (CSBR) has outperformed Black Diamond Therapeutics (BDTX) over the past year, losing 35.9% versus a loss of 65.5%. Over five years, CSBR leads with a -53.0% price change compared with -79.3% for BDTX. Black Diamond Therapeutics is the larger company by market cap ($75.3 million vs $60.4 million), about 1.2 times the size.
Black Diamond Therapeutics converts more of its revenue into profit, with a net margin of 32.0% versus -2.0%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BDTX | CSBR |
|---|---|---|
| Share price | $1.31 | $4.34 |
| Market cap | $75.28M | $60.41M |
| 1-day change | -5.76% | -1.36% |
| YTD return | -46.09% | -37.19% |
| 1-year return | -65.53% | -35.89% |
| 5-year return | -79.30% | -52.98% |
| Forward P/E | — | 43.40 |
| EPS (TTM) | $-0.77 | $-0.07 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $70.00M | $59.42M |
| Revenue growth (YoY) | — | +4.36% |
| Net income (latest FY) | $22.37M | $-1.18M |
| Gross margin | — | 48.00% |
| Operating margin | 17.89% | -1.92% |
| Net margin | 31.95% | -1.98% |
| 52-week high | $3.97 | $8.31 |
| 52-week low | $1.31 | $4.34 |
| Distance from 52-week high | -67.00% | -47.77% |
| Analyst consensus | none | — |
| Avg. price target upside | +663.36% | — |
| Average volume | 697.70K | 9.71K |
| Shares outstanding | 57.47M | 13.92M |
| Employees | 21 | 214 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CSBR has outperformed BDTX by 29.6 percentage points over the past year.
- Black Diamond Therapeutics is more profitable, keeping 32.0 cents of every revenue dollar as net income versus -2.0 cents for Champions Oncology.
About Black Diamond Therapeutics
BDTX stock →Black Diamond Therapeutics, Inc., a clinical-stage oncology company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is silevertinib, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in Phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as Phase 2 clinical trial to treat glioblastoma.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 21 employees
About Champions Oncology
CSBR stock →Champions Oncology, Inc., a technology-enabled research company, provides technology solutions for drug discovery and development in the United States. The company provides personalized cancer care based upon the implantation of human tumors in immune-deficient mice through TumorGraft Technology Platform.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 214 employees
BDTX vs CSBR FAQ
Which is bigger, Black Diamond Therapeutics or Champions Oncology?
Black Diamond Therapeutics (BDTX) is larger, with a market capitalization of $75.28M compared with $60.41M for Champions Oncology (CSBR).
Which stock has performed better over the past year, BDTX or CSBR?
CSBR returned -35.89% over the past 12 months, compared with -65.53% for BDTX (price return, excluding dividends). Past performance does not predict future results.
Are Black Diamond Therapeutics and Champions Oncology in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.